Cationic Peptide Nanocomplexes for DNA Delivery

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current gene delivery methods, such as viral vectors and lipid/polymer-based non-viral vectors, face challenges like insertional mutagenesis, immune activation, limited cargo capacity, toxicity, and bio-compatibility issues, making them inefficient for delivering nucleic acids into eukaryotic cells, particularly in overcoming the endosomal barrier and achieving high transfection efficiency with low toxicity.

Innovation Solution

Development of nanocomplexes containing cationic peptides with specific arginine, histidine, and cysteine sequences that facilitate efficient DNA condensation, release, and endosomal escape, eliminating the need for oxidative steps and providing high transfection efficiency comparable to commercial agents with minimal cytotoxicity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If viral vectors are used for gene delivery, then transfection efficiency is improved, but safety risks like insertional mutagenesis and immune activation increase

Engineering Contradiction:
Improvetransfection efficiencyVSAvoidsafety risks
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses short peptides (18-22 amino acids) as temporary delivery vehicles instead of persistent viral vectors. These peptide-based nanocomplexes perform their delivery function and are then degraded, avoiding long-term safety concerns while maintaining effective gene delivery to target cells

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

2Object-affected harmful factors

If lipid and polymer based non-viral vectors are used, then safety is improved, but transfection efficiency and ability to overcome endosomal barrier deteriorate

Engineering Contradiction:
ImprovesafetyVSAvoidtransfection efficiency
Core Design Contradiction:
Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent creates composite nanocomplexes combining cationic peptides with nucleic acids. The peptide component provides endosomal escape capability through membrane interaction, while the nucleic acid cargo maintains safety. This composite structure achieves both high transfection efficiency and safety by leveraging the complementary properties of its components

Inventive Principle:
Principle #40Composite materials

Solution Approach 2:

The patent optimizes peptide parameters including amino acid composition (arginine, histidine, lysine ratios), molecular weight (1-5 kDa), and charge density to enhance endosomal escape. By adjusting these parameters, the nanocomplexes achieve efficient cellular uptake and endosomal rupture while maintaining biocompatibility and safety

Inventive Principle:
Principle #35Parameter changes

3Reliability

If complex peptide sequences are designed for high transfection efficiency, then delivery performance is improved, but synthesis complexity and cost increase

Engineering Contradiction:
Improvedelivery performanceVSAvoidsynthesis complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent divides the peptide sequence into functional modules: arginine-rich regions for DNA condensation, histidine residues for endosomal escape, and lysine regions for cellular uptake. This modular segmentation allows systematic optimization of each function independently while simplifying synthesis through standardized peptide chemistry protocols

Inventive Principle:
Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The nanocomplexes achieve remarkable DNA delivery efficiency, overcoming endosomal barriers with high transfection rates and low toxicity, comparable to or exceeding commercial agents, while being simpler and more cost-effective to synthesize, and demonstrating serum stability for broader applicability.

Implementation Method 1

Lysine and arginine-rich peptides are the most promising vectors for plasmid DNA delivery since they can efficiently condense DNA and form nanocomplexes

Methodology Applied
Scientific EffectElectrostatic interaction: Electrostatics

Implementation Method 2

Modification of lysine peptides in these nanocomplexes with histidines in linear as well as branched form have been shown to add endosomal escape property to the DNA condensing system

Methodology Applied
Scientific EffectpH buffering: Phase Change

Data Source

PatentEP2916874B1Nanocomplex containing cationic peptide for biomolecule delivery
Publication Date: 2018.08.29 COUNCIL OF SCI & IND RES
  • EP2916874B1 patent drawingFigure 1A
  • EP2916874B1 patent drawingFigure 1B
  • EP2916874B1 patent drawingFigure 1C

AI summary

The present invention relates to developing an optimally efficient arginine-histidine-cysteine based peptide comprising nanocomplex that can deliver biomolecules across varied cell lines without any oxidative procedure through formation of monodisperse nanoparticles with sizes ranging between 50 and 110 nm.